Novel Marine Compounds: Anticancer or Genotoxic?
AUTOR(ES)
Arif, Jamal M.
FONTE
Hindawi Publishing Corporation
RESUMO
In the past several decades, marine organisms have generously gifted to the pharmaceutical industries numerous naturally bioactive compounds with antiviral, antibacterial, antimalarial, anti-inflammatory, antioxidant, and anticancer potentials. But till date only few anticancer drugs (cytarabine, vidarabine) have been commercially developed from marine compounds while several others are currently in different clinical trials. Majority of these compounds were tested in the tumor xenograft models, however, lack of anticancer potential data in the chemical- and/or oncogene-induced pre-initiation animal carcinogenesis models might have cost some of the marine anticancer compounds an early exit from the clinical trials. This review critically discusses importance of preclinical evaluation, failure of human clinical trials with certain potential anticancer agents, the screening tests used, and choice of biomarkers.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=548801Documentos Relacionados
- Environmental N-Nitroso Compounds: Analysis and Formation
- Bioprospecting Anticancer Compounds from the Marine-Derived Actinobacteria Actinomadura sp. Collected at the Saint Peter and Saint Paul Archipelago (Brazil)
- Growth of Pseudomonas C on C1 Compounds: Continuous Culture
- Growth of Pseudomonas C on C1 compounds: a correction.
- Metabolism of quaternary carbon compounds: 2,2-dimethylheptane and tertbutylbenzene.